Topic

GLP-1 & Metabolic Health

The GLP-1 drug era, read on endpoints: head to head trials, body composition, and what happens when the treatment stops being the story and the comparison starts.

Retatrutide Takes Weight Off. Viking Bets a Monthly Shot Keeps It

Retatrutide's 20.8% assumes nobody quit, and Viking's 90% comes from a group of 11. The numbers behind the two biggest obesity drug headlines of September.

CagriSema and EloraTZP Both Beat Tirzepatide. Read the Doses

Novo won at the low end of the dose range, 12.4 versus 9.1 percent. Lilly won at the top, 23.3 versus 14.8, and lost up to one patient in four to side effects.

A GLP-1 Pill Against Insulin: What ACHIEVE-4 Proved for the Heart

Orforglipron cleared a heart safety bar against insulin glargine, 4.2 versus 5.0 percent, and posted a mortality gap the trial was never built to prove.

The Pill Duel: Orforglipron Beats Oral Semaglutide Head to Head

ACHIEVE-3, 1,698 adults, 52 weeks: in the primary analysis HbA1c fell 1.91 points against 1.47. A real head to head, run by one of the duelists.

The Race to Keep Muscle on GLP-1s Reaches Phase 2

Sironax's FORGE-LM trial is half enrolled. The endpoint is body composition, which is the right question. Enrollment, though, is not a result.